Compare Bristol-Myers Squibb Co (BMY) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Uranium Energy Corp — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Uranium Energy Corp trades at $10.48 (market cap $5.14B). The key difference: Bristol-Myers Squibb Co is far larger — about 22.6× Uranium Energy Corp's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.
| BMY | UEC | |
|---|---|---|
Market Cap | $116.30B | $5.14B |
Sector | Health | Energy |
52-Week High | $62.37 | $20.14 |
52-Week Low | $42.60 | $6.98 |
Enterprise Value | $152.24B | $4.65B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Uranium Energy (UEC) trades at $10.07, down 4.37% today, reflecting ongoing operational challenges. The stock shows a bearish technical trend with key support at $10. Fundamentally, the company reported a net loss of $87.66 million in 2025 on $66.84 million revenue, with negative margins and a high P/S ratio of 242.83. Recent news highlights strategic positioning in U.S. uranium production but notes execution risks and cost pressures.
The outlook remains speculative; UEC's $794 million liquidity and debt-free balance sheet support growth initiatives, but persistent losses and volatile earnings create significant risk. Analyst consensus is 87.5% buy, targeting production ramp-ups, yet investors face uncertainty from licensing delays and uranium price fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
